Literature DB >> 10211889

Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation.

E Csernok1, A Trabandt, A Müller, G C Wang, F Moosig, J Paulsen, A Schnabel, W L Gross.   

Abstract

OBJECTIVE: To determine whether a specific cytokine pattern (type 1 [Th1] or type 2 [Th2]) predominates in Wegener's granulomatosis (WG), by evaluating interferon-gamma (IFNgamma) and interleukin-4 (IL-4) expression in different compartments of the body (i.e., biopsied nasal mucosal tissue [NBS], bronchoalveolar lavage [BAL] fluid, and peripheral blood [PB]) and comparing the findings with those in disease and healthy control subjects.
METHODS: Competitive reverse transcriptase-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay were used to assess IFNgamma and IL-4 expression in T cell clones (TCC), T cell lines (TCL), and polyclonal CD4+ and CD8+ cells derived from NBS, BAL, and PB.
RESULTS: Patients with WG and chronic rhinitis were found to share in situ production of messenger RNA (mRNA) specific for IFNgamma (Th1). Only 2 patients with WG expressed IL-4, whereas IL-4 mRNA PCR products were found in inflamed tissues of the disease control patients. The granuloma-derived T cells of WG patients produced only IFNgamma, while TCC, TCL, and CD4+ and CD8+ T cells from BAL and PB produced mainly IFNgamma.
CONCLUSION: Our data indicate that a Thl cytokine pattern predominates in the granulomatous inflammation in patients with WG.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10211889     DOI: 10.1002/1529-0131(199904)42:4<742::AID-ANR18>3.0.CO;2-I

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  52 in total

Review 1.  Perspective on future therapy of vasculitis.

Authors:  D T Boumpas; H D Kritikos; N G Daskalakis
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

2.  Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis.

Authors:  C E Balding; A J Howie; A B Drake-Lee; C O Savage
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

3.  Elevated monocytic IL-12 and TNF-alpha production in Wegener's granulomatosis is normalized by cyclophosphamide and corticosteroid therapy.

Authors:  P Lamprecht; G Kumanovics; A Mueller; E Csernok; A Komocsi; A Trabandt; W L Gross; A Schnabel
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 4.  Cellular aspects of vasculitis--T cell-mediated aspects.

Authors:  M E Griffith; C D Pusey
Journal:  Springer Semin Immunopathol       Date:  2001

5.  Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis.

Authors:  Andras Komocsi; Peter Lamprecht; Elena Csernok; Antje Mueller; Konstanze Holl-Ulrich; Ulrike Seitzer; Frank Moosig; Armin Schnabel; Wolfgang Ludwig Gross
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

6.  Immunoregulatory defects of V alpha 24V+ beta 11+ NKT cells in development of Wegener's granulomatosis and relapsing polychondritis.

Authors:  D Takagi; K Iwabuchi; C Iwabuchi; Y Nakamaru; S Maguchi; R Ohwatari; Y Furuta; S Fukuda; S Joyce; K Onoé
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

7.  Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides.

Authors:  Heidemarie Becker; Christian Maaser; Eva Mickholz; Anke Dyong; Wolfram Domschke; Markus Gaubitz
Journal:  Clin Rheumatol       Date:  2006-01-04       Impact factor: 2.980

8.  Nasal Wegener's and skin sarcoid--a rare combination of two granulomatous diseases.

Authors:  A Kuttikat; T Saeed; B Chopra; S Chopra; K Chakravarty
Journal:  Clin Rheumatol       Date:  2005-11-10       Impact factor: 2.980

Review 9.  Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  P Lamprecht
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

10.  An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).

Authors:  Carol A Langford; Paul A Monach; Ulrich Specks; Philip Seo; David Cuthbertson; Carol A McAlear; Steven R Ytterberg; Gary S Hoffman; Jeffrey P Krischer; Peter A Merkel
Journal:  Ann Rheum Dis       Date:  2013-12-09       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.